

## **RESPONSE TO SPECIES ELECTION REQUIREMENT**

The Examiner requires election of one of hydrocortisone, epidermal growth factor, or bovine brain extract as species of the invention. Office Action at page 2. The Examiner contends that these species are patentably distinct. *Id.* Solely to respond fully to the species election requirement, Applicants elect hydrocortisone. Claims 1-13 and 25-36 are readable on this species. Applicants hereby reserve the right to prosecute claims drawn to other species when generic claims are deemed to be allowable.

The Examiner further requires election of one of HTB-104 cells, CRL-1973 cells, BT483 cells, Hs578T cells, HTB2 cells, BT20 cells or T47D cells as species of the invention. Office Action at page 3. The Examiner contends that these species are patentably distinct. *Id.* Solely to respond fully to the species election requirement, Applicants elect HTB-104 cells. Claims 1-13 and 25-36 are readable on this species. Applicants hereby reserve the right to prosecute claims drawn to other species when generic claims are deemed to be allowable.


Finally, the Examiner requires election of one of acidic fibroblast growth factor (aFGF), angiogenin, basic fibroblast growth factor (bFGF), epidermal growth factor, granulocyte colony stimulating factor (GCSF), interleukin 8 (IL-8), placental growth factor (PGF), platelet-derived growth factor (PDGF), scatter factor (hepatocyte growth factor), transforming growth factor alpha (TGF $\alpha$ ), tumor necrosis factor alpha (TNF $\alpha$ ), vascular endothelial growth factor (VEGF), adenosine, 1-butyryl glycerol, nicotinamide, prostaglandin E1 or prostaglandin E2 as species of the invention. Office Action at page 4. The Examiner contends that these species are patentably distinct. *Id.* Solely to respond fully to the species election requirement, Applicants elect acidic fibroblast growth factor (aFGF). Claims 1-13 and 25-36 are readable on this species. Applicants hereby reserve the right to prosecute claims drawn to other species when generic claims are deemed to be allowable.

### **CONCLUSION**

Applicant respectfully requests that the present remarks be made of record in the file history of the present application. An early allowance of the application is earnestly requested. The Examiner is invited to contact the undersigned with any questions concerning the application. No fee is believed to be due for this response. Should any fee be required, please charge the necessary amount to Jones Day Deposit Account No. 50-3013

Respectfully submitted,

Date: September 21, 2007

  
By: Lawrence S. Graham Reg. No. 49,020  
For: Anthony M. Insogna Reg. No. 35,203

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939